[go: up one dir, main page]

YU43193A - 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi - Google Patents

2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi

Info

Publication number
YU43193A
YU43193A YU43193A YU43193A YU43193A YU 43193 A YU43193 A YU 43193A YU 43193 A YU43193 A YU 43193A YU 43193 A YU43193 A YU 43193A YU 43193 A YU43193 A YU 43193A
Authority
YU
Yugoslavia
Prior art keywords
deoxy
difluoro
intermediates
substituted
pyrimidine
Prior art date
Application number
YU43193A
Other languages
English (en)
Inventor
L.W. Hertel
J.S. Kroin
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of YU43193A publication Critical patent/YU43193A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Opisana su jedinjenja formule (I) gde se Z bira iz grupe H gde je R1 glicin, tio, vodonik, hidrazin, metilamin, 2-metil-hidrazin, etilenhidrazino karboksilat, hidroksiamin, hidrok-simetilamin, karboksilna kiselina, karboksi aldehid karboetoksiamino, aminosulfonil, glicin etil estar, alanin etil estar, karbonitril, nitro, karboksamido, aminometil, ili sulfonil amino grupa; R2 se bira od vodonika, metil, halogena, bromvbinil, amino i njihove farmaceutski prihvatljivih soli. Takođe su opisani međuproizvodi za dobijanje jedinjenja formule I.
YU43193A 1992-06-22 1992-06-21 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi YU43193A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90231492A 1992-06-22 1992-06-22

Publications (1)

Publication Number Publication Date
YU43193A true YU43193A (sh) 1997-01-08

Family

ID=25415673

Family Applications (1)

Application Number Title Priority Date Filing Date
YU43193A YU43193A (sh) 1992-06-22 1992-06-21 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi

Country Status (21)

Country Link
US (1) US5430026A (sh)
EP (1) EP0576230B1 (sh)
JP (1) JPH0656876A (sh)
KR (1) KR940005657A (sh)
CN (1) CN1084177A (sh)
AT (1) ATE137243T1 (sh)
AU (1) AU664096B2 (sh)
BR (1) BR9302430A (sh)
CA (1) CA2098875A1 (sh)
CZ (1) CZ123193A3 (sh)
DE (1) DE69302330T2 (sh)
DK (1) DK0576230T3 (sh)
ES (1) ES2087657T3 (sh)
FI (1) FI932870A (sh)
GR (1) GR3020064T3 (sh)
HU (1) HUT64769A (sh)
IL (1) IL106079A0 (sh)
MX (1) MX9303711A (sh)
NO (1) NO932289L (sh)
PL (1) PL299414A1 (sh)
YU (1) YU43193A (sh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559222A (en) * 1995-02-03 1996-09-24 Eli Lilly And Company Preparation of 1-(2'-deoxy-2',2'-difluoro-D-ribo-pentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro-β-D-ribo-pentopyranose
GB2321454A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Gemcitabine esters and amides
GB9708611D0 (en) * 1997-04-28 1997-06-18 Univ Cardiff Chemical compounds
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
GB0009486D0 (en) * 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
EP1465615B1 (en) 2002-01-15 2012-08-01 Trustees of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
WO2003068162A2 (en) * 2002-02-14 2003-08-21 Pharmasset Ltd. Modified fluorinated nucleoside analogues
AU2003291726A1 (en) 2002-11-04 2004-06-07 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
EP1581547A2 (en) * 2002-12-03 2005-10-05 Baylor University Compounds resistant to metabolic deactivation and methods of use
US7214791B2 (en) * 2004-07-01 2007-05-08 Shenzhen Hande Technology Co., Ltd. Method for preparation of 2′-deoxy-2′, 2′-difluoro-β-cytidine or pharmaceutically acceptable salts thereof by using 1,6-anhydro-β-d-glucose as raw material
PT1831237E (pt) * 2004-12-17 2008-09-22 Lilly Co Eli Pró-fármaco amida da gemcitabina, suas composições e utilizações
ES2341663T3 (es) * 2005-03-04 2010-06-24 Fresenius Kabi Oncology Limited Intermedio y procedimiento para preparar 2'-desoxi-2',2'-difluoro-d-ribofuranosil nucleosidos enriquecidos en el anomero beta.
CN1693309A (zh) * 2005-04-18 2005-11-09 成都正开生物科技发展有限公司 N4－（取代的氧羰基）－2′，2′－二氟－2′－脱氧胞苷衍生物及其应用
AT502635A1 (de) * 2005-11-09 2007-05-15 Saischek Und Partner Meg Neue 1,3-dithioverbindungen, verfahren zu deren herstellung und ihre verwendung
GB0609178D0 (en) 2006-05-09 2006-06-21 Univ Cardiff Novel compounds
US8299046B2 (en) 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
CA2670099A1 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
RS58486B1 (sr) 2008-01-11 2019-04-30 Reata Pharmaceuticals Inc Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti
NZ588710A (en) 2008-04-18 2012-12-21 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US8258329B2 (en) 2008-04-18 2012-09-04 Reata Pharmaceuticals, Inc. Dehydroandrosterone analogs including an anti-inflammatory pharmacore and methods of use
US7943778B2 (en) 2008-04-18 2011-05-17 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
EP2279197B1 (en) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
DE102011077393A1 (de) * 2011-06-10 2012-12-13 Johannes Reinmüller Antiinfektives Mittel
EA031986B1 (ru) 2012-04-04 2019-03-29 Галозим, Инк. Способ и комбинация для лечения солидной раковой опухоли и набор, содержащий комбинацию
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
KR20150090894A (ko) * 2012-10-29 2015-08-06 코크리스탈 파마, 아이엔씨. 바이러스 감염 및 암 치료용 피리미딘 뉴클레오티드 및 그들의 모노포스페이트 프로드럭
WO2016078160A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 胞苷衍生物及其应用
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
GR1009958B (el) * 2019-04-24 2021-03-18 ΕΝΟΡΑΣΙΣ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΚΑΙ ΙΑΤΡΙΚΩΝ ΥΛΙΚΩΝ ΚΑΙ ΜΗΧΑΝΗΜΑΤΩΝ με δ.τ. "ΕΝΟΡΑΣΙΣ Α.Ε." Παραγωγα γεμσιταβινης και μεθοδοι δημιουργιας παραγωγων γεμσιταβινης

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ZA859008B (en) * 1984-12-04 1987-07-29 Lilly Co Eli The treatment of tumors in mammals
ATE92499T1 (de) * 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
CA1295998C (en) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides and their use as antineoplastic agents
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
EP0688782B1 (en) * 1987-08-28 2002-05-02 Eli Lilly And Company Stereoselective process for preparing protected 2',2'-difluorolactonen
US4914028A (en) * 1988-02-10 1990-04-03 Eli Lilly And Company Method of preparing beta-2',2'-difluoronucleosides
ES2075040T3 (es) * 1988-02-16 1995-10-01 Lilly Co Eli 2',3'-dideoxi-2',2'-difluoronucleosidos.
EP0339161A1 (en) * 1988-04-01 1989-11-02 Merrell Dow Pharmaceuticals Inc. Novel fluorophosphonate nucleotide derivatives
JPH0232093A (ja) * 1988-06-08 1990-02-01 Merrell Dow Pharmaceut Inc 抗レトロウィルスジフルオロ化ヌクレオシド類
AU7558491A (en) * 1990-04-04 1991-10-30 Nycomed Imaging As Nucleoside derivatives

Also Published As

Publication number Publication date
DK0576230T3 (da) 1996-05-20
MX9303711A (es) 1994-05-31
DE69302330D1 (de) 1996-05-30
GR3020064T3 (en) 1996-08-31
JPH0656876A (ja) 1994-03-01
HU9301824D0 (en) 1993-09-28
HUT64769A (en) 1994-02-28
PL299414A1 (en) 1993-12-27
FI932870A (fi) 1993-12-23
EP0576230B1 (en) 1996-04-24
FI932870A0 (fi) 1993-06-21
AU4134893A (en) 1993-12-23
ATE137243T1 (de) 1996-05-15
IL106079A0 (en) 1993-10-20
DE69302330T2 (de) 1996-10-10
CZ123193A3 (en) 1994-04-13
AU664096B2 (en) 1995-11-02
NO932289D0 (no) 1993-06-21
KR940005657A (ko) 1994-03-22
ES2087657T3 (es) 1996-07-16
CA2098875A1 (en) 1993-12-23
US5430026A (en) 1995-07-04
BR9302430A (pt) 1994-01-11
NO932289L (no) 1993-12-23
EP0576230A1 (en) 1993-12-29
CN1084177A (zh) 1994-03-23

Similar Documents

Publication Publication Date Title
YU43193A (sh) 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
ATE314077T1 (de) 5-fluoro-2',3'-ungesättigte pyrimidinnucleoside
NL300247I2 (nl) 2-Halogeen-9-(2-desoxy-2-fluor-bêta-D-arabinofuranosyl)-adeninenucleosiderivaten.
DE19975068I1 (de) Derivate und Analoge der 2-Deoxy-2,3-Didehydro-N-A Cetyl-Neuraminsaeure und ihre Verwendung als antivirale Agentien
DE3851187D1 (de) 3'-azido-2',3'-dideoxyuridin anti-retrovirale zusammensetzung.
NO963138D0 (no) L-Nukleosider for behandling av hepatit-B-virus og Epstein-bar-virus
DE3854297D1 (de) Nucleoside und nucleotide mit antiviraler, antitumoraler, antimetastatischer sowie immunstimulierender wirkung.
FI913236A0 (fi) 9-purinylfosfonsyraderivat.
ATE53588T1 (de) Herstellung von cytosin-nukleosiden.
ES2083458T3 (es) Composicion antivirica.
MX9303709A (es) Nucleosidos de purina substituidos e intermediarios de los mismos, que tienen actividad anti-viral y anti-cancerigena y composicion farmaceutica que los contiene.
ATE111477T1 (de) 2'-halomethyliden, 2'-ethenyliden und 2'-ethynyl- adenosinderivate.
ATE147746T1 (de) Derivate von fluorphosphonat-nukleotiden
DK291390D0 (da) Terapeutiske anvendelser af 2',5'-oligoadenylatderivater
FR2688003B1 (fr) Derives de nucleosides, leur preparation et leurs applications biologiques.
DE68901443D1 (de) Derivate von nukleosiden.
RU93046286A (ru) 2'-дезокси-2', 2'-дифтор (4-замещенный пиримидин)нуклеозиды, обладающие противовирусной и противораковой активностью, промежуточные соединения и способ лечения